版本:
中国

BRIEF-Transgene SA says first results from Phase 2 trial could be expected from end of 2017

March 13 Transgene SA :

* First patient dosed in Phase 2 trial evaluating Transgene's TG4010 in combination with Opdivo(nivolumab) for 2nd line treatment of metastatic non-small cell lung cancer (NSCLC)

* First results from Phase 2 trial could be expected from end of 2017 Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐